Weekly paclitaxel and concurrent pazopanib following doxorubicin and cyclophosphamide as neoadjuvant therapy for HER-negative locally advanced breast cancer: NSABP Foundation FB-6, a phase II study.

Tan, A R; Johannes, H; Rastogi, P; Jacobs, S A; Robidoux, A; Flynn, P J; Thirlwell, M P; Fehrenbacher, L; Stella, P J; Goel, R; Julian, T B; Provencher, L; Bury, M J; Bhatt, K; Geyer, C E; Swain, S M; Mamounas, E P; Wolmark, N

Weekly paclitaxel and concurrent pazopanib following doxorubicin and cyclophosphamide as neoadjuvant therapy for HER-negative locally advanced breast cancer: NSABP Foundation FB-6, a phase II study.

Tan, A R; Johannes, H; Rastogi, P; Jacobs, S A; Robidoux, A; Flynn, P J; Thirlwell, M P; Fehrenbacher, L; Stella, P J; Goel, R; Julian, T B; Provencher, L; Bury, M J; Bhatt, K; Geyer, C E; Swain, S M; Mamounas, E P; Wolmark, N.

Affiliation

Tan AR; National Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation, Pittsburgh, PA, USA, Antoinette.Tan@CarolinasHealthCare.org.

Breast Cancer Res Treat ; 149(1): 163-9, 2015 Jan.

Article in En | MEDLINE | ID: mdl-25542269

Subject(s)

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyrimidines / Sulfonamides / Breast Neoplasms / Doxorubicin / Paclitaxel / Cyclophosphamide Type of study: Clinical_trials Limits: Adult / Aged / Female / Humans / Middle aged Language: En Journal: Breast Cancer Res Treat Year: 2015 Document type: Article Country of publication:

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google